T he function of transforming growth factor b (TGFb) in the progression of pancreatic ductal adenocarcinoma (PDA) is complex and therapeutic targeting of this pathway is challenging. We showed that antibody-mediated inhibition of stromal Tgfbr2 prevented or reversed epithelial plasticity resulting in a potent reduction of metastasis in xenograft models of PDA.
T he function of transforming growth factor b (TGFb) in the progression of pancreatic ductal adenocarcinoma (PDA) is complex and therapeutic targeting of this pathway is challenging. We showed that antibody-mediated inhibition of stromal Tgfbr2 prevented or reversed epithelial plasticity resulting in a potent reduction of metastasis in xenograft models of PDA.
Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States, and has proved to be a formidable challenge with regard to treatment. 1 An elevated level of transforming growth factor b (TGFb) is a negative prognostic indicator for patients diagnosed with pancreatic ductal adenocarcinoma (PDA) and over 50% of human PDAs have mutations in the TGFb pathway.
2 This makes the TGFb pathway an attractive therapeutic target. However, the function of TGFb in the development and progression of PDA is complex and severely dysregulated in advanced tumors. As in other epithelial tumors, TGFb functions as a tumor suppressor early in the development of PDA, but switches to a tumor promoter function late in the disease process. This switch, together with findings that direct neutralization of Tgfb accelerates tumor growth in some mouse models of PDA, makes targeting the TGFb pathway challenging. 3 In this study, we found that selected neutralization of murine Tgfbr2 with a monoclonal antibody (2G8) led to a differentiated epithelial tumor cell phenotype and potent anti-metastatic effects. 4 These effects were seen in multiple mouse models of PDA including 4 xenograft models and syngeneic and genetic (LSL-Kras G12D ; Cdkn2a lox/lox ; p48-Cre) models. In the xenograft setting in particular, these effects can be attributed directly to inhibition of stromal Tgfbr2 because 2G8 is a mousespecific monoclonal antibody.
In each PDA model, Tgfbr2 neutralization significantly reduced metastasis and cell proliferation, while increasing apoptosis in the primary tumor. Interestingly, the effect of 2G8 on primary tumor size was not predictive of the effect on metastasis. In vitro data corroborated these findings, as 2G8 had no effect on tumor cell viability. However, 2G8 reduced a stimulatory effect of conditioned media from murine stromal cells on tumor cell migration and anchorage-independent growth. Together, the in vivo metastasis data and in vitro characterization studies strongly implicate stromal Tgfbr2 as a critical driver of PDA dissemination. These results are consistent with the characterization of primary tumor tissue in each model after treatment with 2G8. 2G8 consistently reduced the level of activated fibroblasts, collagen deposition, and microvessel density associated with primary PDA. These observations are concordant with Tgfbr2 as a regulator of ECM deposition and the fibroblast phenotype in the PDA microenvironment. Arguably though, the most interesting finding was the effect on tumor cell epithelial to mesenchymal transition (EMT); tumors treated with 2G8 displayed a more epithelial or differentiated phenotype than tumors exposed to control or gemcitabine alone. This is demonstrated convincingly in the genetic and syngeneic models of PDA (Fig. 1) . In the genetic model, 2G8-treated mice had significantly more pancreatic intraepithelial Bar graphs represent meanC/¡SEM. **, P < 0.01; #, P < 0.0001 vs. control;^^, P < 0.001;^^^, P < 0.0001 vs. Gem. Reproduced with permission from Ostapoff et al.
marker of mesenchymal cells and/or cells undergoing EMT. These dramatic phenotypic effects were dependent on the presence of stromal cells because treatment of PDA cells in vitro with 2G8 could not drive epithelial differentiation. TGFb is a pleiotrophic cytokine that also promotes immune suppression. 3, [5] [6] [7] [8] In this study, 2G8 reversed the immune suppressive effects of Tgfb as demonstrated by an increase in the ratio of pro-inflammatory M1 to anti-inflammatory M2 macrophages (M1:M2) and natural killer (NK) cells, with a concomitant decrease in myeloid-derived suppressor cells (MDSCs) and T regulatory cells. Although we did not specifically evaluate effects on T-and B-cell immunity in this study, our findings were concordant in immunocompromised (xenograft) and immunocompetent models, demonstrating that blockade of stromal Tgfbr2 promotes a proinflammatory phenotype. However, the contribution of these changes to the promotion of a differentiated tumor cell phenotype and the reduction in metastasis remains to be elucidated. It is plausible that 2G8 induction of NK cell activity is critical for the antimetastatic activity observed given the results of Zhong et al., who observed that 2G8 induced an increase in NK cell infiltration and killing activity in syngeneic breast tumors. 9 Overall, this study further defines the importance of stromal TGFb signaling in the development and progression of PDA.
Pharmacologic blockade of Tgfbr2 resulted in a proinflammatory immune cell phenotype, a decrease in mature/activated fibroblasts, and a decrease in collagen deposition. These microenvironmental changes occurred in concert with tumor cell epithelial differentiation and a reduction in metastasis, leading us to conclude that Tgfb signaling within stromal cells has a direct influence on pancreatic tumor cell phenotype and pancreatic cancer progression. Whether this impact is secondary to a distinct soluble factor released into the tumor microenvironment, or to effects on other cells in the microenvironment such as pancreatic stellate cells, mesenchymal stem cells, and endothelial cells, remains to be seen. We suspect that the complexity of TGFb biology in cancer is intimately tied to the interplay between stromal cells and the tumor cells that recruit them. We propose that signaling through TGFbR2 on stromal cells is a requisite pathway for a subset of tumors that stimulates the release of prometastatic soluble factors from stromal cells. Identifying tumors that rely on this pathway and the factors that are produced by stromal cells in response to activation of TGFbR2 are remaining challenges.
